AGO2 and glioma: Results showed that IGF2BP3 loss led to the notable reduction of ZNRF3 level enriched by Ago2 antibody in U251 cells (Fig. 6D), suggesting that IGF2BP3 knockdown weakened the interaction of ZNRF3 and RISC in glioma cells.